Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pivotal randomized trial of GS010 (rAAV2/2-ND4) for Leber hereditary optic neuropathy (G11778A) with 6–12 months disease duration
2015-001266-26Phase 3Completed
- Sponsor
- GenSight Biologics
- Start
- Aug 2015
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lenadogene nolparvovec in Leber hereditary optic neuropathy (LHON) (2 arms), sponsored by GenSight Biologics. Primary endpoint: Change in ETDRS visual acuity (LogMAR) at week 48. Started Aug 2015; status: completed.
02
Drugs
lenadogene nolparvovec
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on 2015-001266-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001266-26.